Table 1.
HoxB13(G84E) mutations in prostate cancer.
| Author | PMID | Study year | Patient population | Age of PrCa Onset G84E Carrierh | Study typei | Genotyping assay | Sample # |
Cancer cases |
Non-cancer controls |
OR (95% CI) | P-value | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cancer | Non-cancer | Mutation | Non-mutation | Mutation | Non-mutation | |||||||||
| Akbari | 22781434 | 2012 | Multiple ethnicities, multiple countries | 59.4 | HB | Sanger sequencing | 1853 | 2225 | 10 | 1843 | 2 | 2223 | 5.8 (1.3–26.5) | 0.01 |
| Albitar F | 25874003 | 2015 | USA, Caucasian | NR | HB | Sanger sequencing | 232 | 110 | 2 | 230 | 1 | 109 | 0.95 (0.09–10.6) | 0.97 |
| Beebe-Dimmera | 26108461 | 2015 | Mayo Clinic Biobank, Primarily Caucasian | NR | HB | Taq-Man | 42 | 7218 | 19 | 23 | 1343 | 5875 | 1.99 (1.37–2.90) | <0.0001 |
| Breyer | 22714738 | 2012 | Multiple countries, multiple ethnicities | 53.4 | HB | Taq-Man | 928 | 930 | 20 | 908 | 2 | 928 | 7.9 (1.8–34.5) | 0.0062 |
| Chen | 23393222 | 2013 | Multiple countries, multiple ethnicities | NR | HB | iPLEX MassARRAY | 20 | 3887 | 7 | 13 | 701 | 3186 | RR = 2.45 (1.48–4.07) | 0.01 |
| Ewing* | 22236224 | 2012 | USA, Caucasian | 52.6 | HB | Taq-Man | 5083 | 2662 | 72 | 5011 | 4 | 2658 | 20.1 (3.5–803.3) | 8.50E-07 |
| Gudmundssona | 23104005 | 2012 | Chicago-SPORE, Caucasian | 58.3 | HB | Illumina SNP Chips | 1988 | 1260 | 11 | 1971 | 5 | 1255 | 1.40 (0.49–4.04) | 5.30E-01 |
| Gudmundssonb | 23104005 | 2012 | Iceland, Caucasian | 66.2 | HB | Illumina SNP Chips | 4537 | 54444 | 13 | 4524 | 44 | 54400 | 3.55 (1.91–6.60) | 1.00E-04 |
| Gudmundssonc | 23104005 | 2012 | Netherlands, Caucasian | 63.9 | HB/PB | Illumina SNP Chips | 1520 | 1916 | 23 | 1497 | 4 | 1912 | 7.34 (2.53–21.3) | 3.90E-10 |
| Gudmundssond | 23104005 | 2012 | Spain, Caucasian | NR | HB | Illumina SNP Chips | 717 | 1692 | 1 | 716 | 0 | 1692 | 7.09 (0.29–174.2) | 2.30E-01 |
| Gudmundssone | 23104005 | 2012 | United Kingdom, Caucasian | 61.7 | HB | Illumina SNP Chips | 561 | 1825 | 6 | 505 | 1 | 1824 | 21.67 (2.60–180.4) | 4.40E-03 |
| Gudmundssonf | 23104005 | 2012 | Romanian, Caucasian | 69.4 | HB | Illumina SNP Chips | 722 | 857 | 1 | 721 | 1 | 856 | 1.19 (0.07–19.0) | 9.31E-01 |
| Karlssona | 22841674 | 2014 | Swedish, Caucasian | NR | PB | iPLEX MassARRAY | 2805 | 1709 | 130 | 2675 | 24 | 1685 | 3.4 (2.2–5.4) | 6.40E-10 |
| Karlssonb | 22841674 | 2014 | Swedish, Stockholm-1 group, Caucasian | NR | HB | iPLEX MassARRAY | 2098 | 2880 | 91 | 2007 | 37 | 2843 | 3.5 (2.4–5.2) | 2.00E-11 |
| Kluzniak | 23334858 | 2013 | Polish, caucasian | 67.3 | PB | Taq-Man | 3515 | 2604 | 20 | 3495 | 3 | 2601 | 4.96 (1.47–16.7) | 0.0097 |
| Kote-Jarai | 25595936 | 2015 | United Kingdom, Caucasian | NR | HB | Taq-Man | 8652 | 5252 | 134 | 8518 | 28 | 5224 | 2.94 (1.95–4.42) | <0.0001 |
| Laitinen | 23292082 | 2013 | Finnish, Caucasian | <=55 | HB/PB | Multiple methods | 4571 | 923 | 160 | 4411 | 28 | 895 | 1.15 (0.77–1.74) | 0.47 |
| MacInnis | 23457453 | 2013 | Australian, caucasian | 52.7 | PB | Taq-Man | 1384 | N/A | 19 | 1365 | N/A | N/A | Incidence: 16.4 (2.5–107.2) | N/A |
| Storebjerg | 26779768 | 2016 | Danish | 61.7 | HB | Sanger sequencing | 995 | 1622 | 25 | 970 | 8 | 1614 | 5.12 (0.26–13.38) | 1.30E-05 |
| Stott-Miller | 23129385 | 2013 | USA, Caucasian | NR | PB | Taq-Man | 1457 | 1442 | 18 | 1439 | 5 | 1437 | 3.6 (1.3–9.7) | 0.01 |
| Witte | 23396964 | 2013 | Multiple countries, multiple ethnicities | NR | FB/HB | Taq-Man | 1645 | 1019 | 20 | 1625 | 3 | 1016 | 4.17 (1.24–14.1) | 0.02 |
| Xu | 23064873 | 2013 | Multiple countries, caucasian | 62.8 | FB | iPLEX MassARRAY | 326 | 117 | 154 | 172 | 36 | 81 | 2.01 (1.29–3.16) | 0.002 |
a, b, c, d, e, f: Data from multiple populations present within a single study.
h: Not reported.
i: FB = Family Based; HB = Hospital Based; PB = Population Based.